Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal

1992 ◽  
Vol 126 (2) ◽  
pp. 179-183 ◽  
Author(s):  
Jean-Louis Sadoul ◽  
Antoine Thyss ◽  
Pierre Freychet
Keyword(s):  
Growth Hormone ◽  
Tumour Growth ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Clinical Signs ◽  
Treatment Protocol ◽  
Pituitary Tumour ◽  
Prolactin Secretion ◽  
Close Monitoring ◽  
Complete Control

Octreotide and bromocriptine were used to treat an acromegalic patient harbouring an invasive pituitary tumour secreting growth hormone and prolactin. Octreotide (100 μg, subcutaneously, three times daily) and bromocriptine (15 mg orally, daily) rapidly improved clinical signs and symptoms, including diabetes that initially required insulin. Complete control of growth hormone and prolactin secretion was obtained and maintained by this treatment protocol for 12 months without affecting the other pituitary functions. A major tumour shrinkage was apparent by magnetic resonance imaging after six months, and was considered to be complete after 12 months of treatment. Octreotide was then discontinued without any relapse in either growth hormone secretion or tumour growth over a 20-month period following withdrawal. Attempts were made to discontinue bromocriptine, but a maintenance therapy (2.5 mg daily) was required to control rebounds of prolactin hypersecretion. Two months after octreotide withdrawal, acute pancreatitis secondary to cholelithiasis required surgery; this complication was attributed to octreotide (pre-treatment ultrasonography was normal). These findings suggest that combination therapy with octreotide and bromocriptine may be considered in pituitary macroadenomas secreting growth hormone and prolactin. They also emphasize the need for a close monitoring of cholelithiasis, not only during octreotide therapy but also after the drug's withdrawal.

Fleece growth in Australian cashmere goats. III. The seasonal patterns of cashmere and hair growth, and association with growth hormone, prolactin and thyroxine in blood

1993 ◽  
Vol 44 (5) ◽  
pp. 1035 ◽  
Author(s):  
WRL Kloren ◽  
BW Norton ◽  
MJ Waters
Keyword(s):  
Growth Hormone ◽  
Hair Growth ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Growth Cycle ◽  
Prolactin Secretion ◽  
Seasonal Patterns ◽  
Hormone Concentration ◽  
Active Growth ◽  
Cashmere Goats

The seasonal patterns of cashmere and hair growth, and prolactin, thyroxine and growth hormone concentration in blood were investigated in male, female and castrated male 6- month-old Australian cashmere goats for 27 months. Seasonal patterns of cashmere growth were distinct with length increasing from a minimum in December to maximum (50-60 mm) in July. Initiation of cashmere growth in female goats was consistently earlier than that of males, with that of castrates being similar, later and earlier than males in 1987, 1988 and 1989 respectively. The initiation of cashmere growth progressed in a wave from the hip to the shoulder (6 weeks). There were no significant effects of sex on maximum length of cashmere grown. Prolactin secretion was also seasonal, increasing from minimum values in July-August (20 ng/mL) to peak levels around December (50-350 ng/mL). Thyroxine concentrations were higher in summer than winter, but seasonal changes were not as distinct as those of prolactin. Growth hormone secretion was aseasonal, and declined with age. It has been proposed that peak levels of prolactin in December were associated with the initiation of cashmere growth, with active growth occurring as levels declined. Neither thyroxine nor growth hormone appear to have a regulatory influence on the cashmere growth cycle.

DNA SYNTHESIS AND DEPLETION OF PROLACTIN IN THE PITUITARY GLAND OF THE MALE RAT

1978 ◽  
Vol 77 (1) ◽  
pp. 129-136 ◽  
Author(s):  
H. M. LLOYD ◽  
J. M. JACOBI ◽  
J. D. MEARES
Keyword(s):  
Growth Hormone ◽  
Dna Synthesis ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Prolactin Secretion ◽  
Male Rats ◽  
Male Rat ◽  
Serum Prolactin ◽  
Inhibitory Effects ◽  
Pituitary Prolactin

Haloperidol, bromocriptine and diethylstilboestrol dipropionate were given in various régimes to male rats to determine their effects on pituitary DNA synthesis, prolactin secretion and growth hormone secretion. Haloperidol increased serum prolactin but did not stimulate pituitary DNA synthesis or reduce pituitary prolactin concentrations. Haloperidol potentiated the effects of oestrogen on serum prolactin and on pituitary DNA synthesis; pituitary prolactin concentrations were greatly reduced, and growth hormone secretion was slightly inhibited. The inhibitory effects of bromocriptine in oestrogen-stimulated rats were demonstrated by smaller pituitary weights and decreased DNA synthesis; serum prolactin levels were lowered and pituitary prolactin concentrations were increased. Haloperidol, given to rats treated with oestrogen and bromocriptine, reversed the inhibitory effects of bromocriptine on DNA synthesis and serum prolactin; pituitary prolactin concentrations fell to well below normal. The results suggest that the haloperidol potentiation of oestrogeninduced pituitary DNA synthesis may depend upon stimulation of prolactin secretion together with reduction of intracellular prolactin levels.

scholarly journals Suppression of sleep-related prolactin secretion and enhancement of sleep-related growth hormone secretion.

1975 ◽  
Vol 56 (3) ◽  
pp. 690-697 ◽  
Author(s):  
W B Mendelson ◽  
L S Jacobs ◽  
J D Reichman ◽  
E Othmer ◽  
P E Cryer ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Prolactin Secretion

scholarly journals Thyroliberin action in pituitary cells is not inhibited by pertussis toxin

1986 ◽  
Vol 237 (1) ◽  
pp. 181-186 ◽  
Author(s):  
P M Hinkle ◽  
E L Hewlett ◽  
M C Gershengorn
Keyword(s):  
Growth Hormone ◽  
Pertussis Toxin ◽  
Inositol Phosphate ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Pituitary Tumour ◽  
Pituitary Cells ◽  
Guanine Nucleotide ◽  
Muscarinic Agonists ◽  
Prolactin Synthesis

The effects of pertussis toxin on the responses of rat pituitary-tumour (GH) cells to thyrotropin-releasing hormone (thyroliberin, TRH) were examined. Treatment of cells with pertussis toxin did not alter the affinity or concentration of TRH receptors, or the sensitivity of the TRH receptor to inhibition by guanine nucleotides. TRH caused an increase in low-Km GTPase activity in membrane-containing fractions from both control and pertussis-toxin-treated cells. TRH stimulation of inositol phosphate formation was insensitive to pertussis toxin. TRH caused a biphasic increase in the concentrations of cytosolic free Ca2+ as monitored by intracellularly trapped Quin 2, and this increase was the same in control and toxin-treated cultures. The toxin did not alter the increase in prolactin and growth-hormone (somatotropin) release stimulated by TRH or shift the TRH dose-response curve, and it did not affect the TRH-induced rise in prolactin synthesis measured over 24 h. However, pertussis toxin did block the ability of somatostatin and muscarinic agonists to inhibit prolactin and growth-hormone secretion stimulated by vasoactive intestinal peptide when analysed under the same conditions as those in which the TRH system was unaffected. These data indicate that the guanine nucleotide effects on TRH binding and activity are not mediated by Ni, but possibly by another member of the family of guanine-nucleotide-dependent regulatory proteins.

EFFECT OF BROMOCRIPTINE, ERGOTAMINE AND OTHER ERGOT ALKALOIDS ON THE HORMONE SECRETION AND GROWTH OF A RAT PITUITARY TUMOUR

1980 ◽  
Vol 86 (1) ◽  
pp. 147-153 ◽  
Author(s):  
R. A. PRYSOR-JONES ◽  
J. S. JENKINS
Keyword(s):  
Growth Hormone ◽  
Inhibitory Action ◽  
Tumour Growth ◽  
Hormone Secretion ◽  
Ergot Alkaloids ◽  
Pituitary Tumour ◽  
Rat Pituitary ◽  
Dopaminergic Mechanisms ◽  
Excessive Secretion

The effect of bromocriptine on hormone secretion and the growth of the prolactin- and growth hormone (GH)-secreting rat pituitary tumour of the GH3 cell line has been compared with that of ergotamine and other ergot alkaloids. Bromocriptine in doses ranging from 1 to 20 mg/kg had no effect on tumour growth or on the excessive secretion of GH by the tumour; prolactin concentrations were reduced only by the highest dosage of the drug. Similarly the tumour was resistant to the administration of ergocryptine, ergocornine and the synthetic ergolines, lergotrile and CH 29–717. In contrast, ergotamine reduced secretion of both GH and prolactin and considerably inhibited the growth of the tumour. Experiments in vitro showed that ergotamine inhibited DNA synthesis of the tumour cells and decreased hormone secretion. It was concluded that ergotamine had a direct inhibitory action on the GH3 cell tumour which was not mediated through the dopaminergic mechanisms.

Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans

2002 ◽  
Vol 283 (5) ◽  
pp. E1008-E1015 ◽  
Author(s):  
Craig A. Jaffe ◽  
D. Kim Turgeon ◽  
Kenneth Lown ◽  
Roberta Demott-Friberg ◽  
Paul B. Watkins
Keyword(s):  
Gender Differences ◽  
Growth Hormone ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Treatment Protocol ◽  
Metabolic Effects ◽  
Gh Secretion ◽  
Igf I ◽  
Daily Dose ◽  
Igfbp 3

The importance of gender-specific growth hormone (GH) secretion pattern in the regulation of growth and metabolism has been demonstrated clearly in rodents. We recently showed that GH secretion in humans is also sexually dimorphic. Whether GH secretion pattern regulates the metabolic effects of GH in humans is largely unknown. To address this question, we administered the same daily intravenous dose of GH (0.5 mg · m−2 · day−1) for 8 days in different patterns to nine GH-deficient adults. Each subject was studied on four occasions: protocol 1 (no treatment), protocol 2 (80% daily dose at 0100 and 10% daily dose at 0900 and 1700), protocol 3 (8 equal boluses every 3 h), and protocol 4 (continuous GH infusion). The effects of GH pattern on serum IGF-I, IGF-binding protein (IGFBP)-3, osteocalcin, and urine deoxypyridinoline were measured. Hepatic CYP1A2 and CYP3A4 activities were assessed by the caffeine and erythromycin breath tests, respectively. Protocols 3 and 4 were the most effective in increasing serum IGF-I and IGFBP-3, whereas protocols administering pulsatile GH had the greatest effects on markers of bone formation and resorption. All GH treatments decreased CYP1A2 activity, and the effect was greatest for pulsatile GH. Pulsatile GH decreased, whereas continuous GH infusion increased, CYP3A4 activity. These data demonstrate that GH pulse pattern is an independent parameter of GH action in humans. Gender differences in drug metabolism and, potentially, gender differences in growth rate may be explained by sex-specific GH secretion patterns.

LONG-TERM TREATMENT OF ACROMEGALY WITH BROMOCRIPTINE

1978 ◽  
Vol 87 (4) ◽  
pp. 687-700 ◽  
Author(s):  
Peter Claes Eskildsen ◽  
Per Aaby Svendsen ◽  
Lisbeth Vang ◽  
Jørn Nerup
Keyword(s):  
Growth Hormone ◽  
Hormone Secretion ◽  
Visual Fields ◽  
Growth Hormone Secretion ◽  
Term Treatment ◽  
Prolactin Secretion ◽  
Plasma Growth Hormone ◽  
Free Cortisol ◽  
Long Term Treatment

ABSTRACT Treatment with bromocriptine, 30–55 mg daily, in 13 acromegalics for 1–15 months, resulted in a 60 % decrease in growth hormone secretion, as judged from the excretion of growth hormone in 24-h urine. Normal excretion was obtained in 10 patients, while 1 patient showed no response. The plasma growth hormone response to O-GTT was improved, but not normalized, in 4 of 7 patients treated for more than 6 months, and marked glucosuria disappeared in two diabetics. While the secretion of TSH, LH and FSH was unchanged, the prolactin secretion was inhibited. The urine excretion of free cortisol showed a 30 % decrease, possibly due to a direct effect of bromocriptine on the ACTH-secretion. Hypercalcaemia was never seen, but the initial hypercalcuria showed a modest decrease without measurable changes in the creatinine clearance. The subjective relief during long-term treatment was marked in 10 of 11 patients and the dominating symptoms disappeared in 40–67 %, whereas heal-pad thickness, enlarged sellae, and visual fields remained unchanged. No serious side effects were observed. Treatment with bromocriptine seems effective and should be considered as a remedy amongst others, in suitable cases of acromegaly.

Sign in / Sign up

Export Citation Format

Share Document